Journal: Advanced Science

Article Title: Identification of PRDX5 as A Target for The Treatment of Castration‐Resistant Prostate Cancer

doi: 10.1002/advs.202304939

Figure Lengend Snippet: Suppression of CRPC tumor growth by PRDX5 inhibitors A) LNCaP epiDTP and enzDTP cell survivals were reduced by POL with IC 50 of 4.71 µM and 4.15 µM, and by STA with IC 50 of 4.08 µM and 3.82 µM, respectively. B) PRDX5 protein level was not changed by the treatment of POL, STA alone, or in combination with EPI, ENZ as measured by Western blotting. β‐ACTIN protein was used as the loading control. C) Cellular PRDX5 activity was measured by enzymatic assay in the presence of POL, STA, EPI, PRDX5 protein, or siPRDX5 alone or in combination. PRDX5 activity was inhibited by POL, STA, and siPRDX5, but increased by PRDX5 protein. D) Cell death rate (%) was measured by LDH release assay in the presence of POL, STA, EPI, PRDX5 protein, or siPRDX5 alone or in combination. Data are expressed as mean ± std of triplicates. One‐way ANOVA with the Turkey test was performed. p <0.05 was considered significant and indicated by different letters. E) PRDX5 inhibitor slowed down CRPC progression in mice. Weight and photograph of the prostate are shown from MYC T mice (6 per group) treated with enzalutamide (ENZ), abiraterone (ABI), polaprezinc (POL), stachyose (STA), or in combinations. AP: anterior prostate lobe, DL: dorsolateral prostate lobe, VP: ventral prostate lobe. Student's t ‐test was performed, ** and ***indicate p <0.01 and p <0.001, respectively. F) Representative images of prostate histopathology. Age and treatment are labeled.

Article Snippet: Enzalutamide (MCE, HY‐70002, NJ, US), EPI‐001 (Selleck, S7955, TX, US), Auranofin (MCE, HY‐B1123, NJ, US), Polaprezinc (MCE, HY‐B0729, NJ, US) and Darolutamide (Selleck, S7559, TX, US) were stored as stock solutions in DMSO (Sigma, MO, US).

Techniques: Western Blot, Control, Activity Assay, Enzymatic Assay, Lactate Dehydrogenase Assay, Histopathology, Labeling

Journal: Journal of Clinical Biochemistry and Nutrition

Article Title: Proton pump inhibitor alone vs proton pump inhibitor plus mucosal protective agents for endoscopic submucosal dissection-induced ulcer: a systematic review and meta-analysis

doi: 10.3164/jcbn.14-101

Figure Lengend Snippet: Characteristics of studies included in the meta-analysis

Article Snippet: Rebamipide {2-(4-chlorobenzoylamino)-3-[2(1H)-quinolinon-4-yl] propionic acid; Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan} exerts a preventive effect on gastric ulcer formation by inhibiting neutrophil activation. ( , ) Rebamipide is an oxygen-radical scavenger, stimulates the generation of cytoprotective prostaglandins, and increases blood flow in the gastric mucosa. ( – ) Ecabet sodium (12-sulfodehydroabietic acid monosodium salt; Mitsubishi Tanabe Pharma Corporation, Osaka, Japan) has protective effects such as endogenous prostaglandins and nitric oxide synthesis and increases blood flow in the gastric mucosa. ( ) Ecabet sodium also exhibits a bactericidal effect against Helicobacter pylori by inhibiting bacterial urease activity. ( ) Polaprezinc [ N -(3-amino propionyl)- l -histidine zinc; Zeria Pharmaceutical Co., Ltd., Tokyo, Japan] promotes ulcer healing with actions such as prostaglandin-independent cytoprotection, antioxidant activity, leukocyte inactivation, and membrane stabilization. ( ) Moreover, polaprezinc stimulates the production of insulin-like growth factor 1, thus promoting mucosal wound healing. ( ) Irsogladine [2,4-diamino-6-(2,5-dichlorophenyl)-s-triazine; Nippon Shinyaku Co., Ltd., Kyoto, Japan] suppresses free radical production, facilitates intercellular communication via gap junctions, and enhances gastric mucosal blood flow. ( ) These actions accelerate mucosal or submucosal reconstruction and enhance the quality of ulcer healing.

Techniques: Protein-Protein interactions

Journal: Journal of Clinical Biochemistry and Nutrition

Article Title: Proton pump inhibitor alone vs proton pump inhibitor plus mucosal protective agents for endoscopic submucosal dissection-induced ulcer: a systematic review and meta-analysis

doi: 10.3164/jcbn.14-101

Figure Lengend Snippet: Pooled Odds ratio and its 95% CI in the studies of each mucosal protective agent

Article Snippet: Rebamipide {2-(4-chlorobenzoylamino)-3-[2(1H)-quinolinon-4-yl] propionic acid; Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan} exerts a preventive effect on gastric ulcer formation by inhibiting neutrophil activation. ( , ) Rebamipide is an oxygen-radical scavenger, stimulates the generation of cytoprotective prostaglandins, and increases blood flow in the gastric mucosa. ( – ) Ecabet sodium (12-sulfodehydroabietic acid monosodium salt; Mitsubishi Tanabe Pharma Corporation, Osaka, Japan) has protective effects such as endogenous prostaglandins and nitric oxide synthesis and increases blood flow in the gastric mucosa. ( ) Ecabet sodium also exhibits a bactericidal effect against Helicobacter pylori by inhibiting bacterial urease activity. ( ) Polaprezinc [ N -(3-amino propionyl)- l -histidine zinc; Zeria Pharmaceutical Co., Ltd., Tokyo, Japan] promotes ulcer healing with actions such as prostaglandin-independent cytoprotection, antioxidant activity, leukocyte inactivation, and membrane stabilization. ( ) Moreover, polaprezinc stimulates the production of insulin-like growth factor 1, thus promoting mucosal wound healing. ( ) Irsogladine [2,4-diamino-6-(2,5-dichlorophenyl)-s-triazine; Nippon Shinyaku Co., Ltd., Kyoto, Japan] suppresses free radical production, facilitates intercellular communication via gap junctions, and enhances gastric mucosal blood flow. ( ) These actions accelerate mucosal or submucosal reconstruction and enhance the quality of ulcer healing.

Techniques:

Journal: In Vivo

Article Title: Protective Effect of Polaprezinc and Hyperbaric Oxygen Therapy on Radiation-induced Small Intestinal Damage in Mice

doi: 10.21873/invivo.12948

Figure Lengend Snippet: Parentheses: standard deviation, *p<0.01 vs. Radiation alone, **p=0.0035 vs. Polaprezinc, ***p<0.0001 vs. Hyperbaric oxygen.

Article Snippet: Polaprezinc (Promac, ZERIA Pharmaceutical Co., Ltd., Tokyo, Japan) was given 2 h before radiation in 12 mice.

Techniques: Standard Deviation